Toggle navigation menu
Home
About
Acorda
Company
Leadership
Management Team
Board of Directors
Partnering
With Acorda
Grant
Program
Scientific
Award
Compliance
Acorda Compliance
Biotie EFPIA Discolsures
Message From
BIO
Diversity and
Inclusion
Contact Us
For
Patients
Focus On
Therapies
In the
Community
Resources
Policy on Access to
Unapproved Medicines
Products &
Research
Pipeline
ARCUS® Technology
Products
AMPYRA®
(dalfampridine)
INBRIJA™
(levodopa inhalation powder)
Clinical
Trials
Terms and Conditions
(Product Purchases)
Investors
Corporate
Governance
Stock
Information
Investor Events
Investor News
Financial
Information
Quarterly Updates
Annual Reports
SEC Filings
Analysts
Investor
Resources
Investor Kit
E-mail Alerts
FAQs
IR Contact
News &
Events
In the News
Awards
Press Releases
Social Media
Careers
Working at
Acorda
Our
Employees
Benefits
Job Openings
Application
Home
About
Acorda
Company
Leadership
Management Team
Board of Directors
Partnering
With Acorda
Grant
Program
Scientific
Award
Compliance
Acorda Compliance
Biotie EFPIA Discolsures
Message From
BIO
Diversity and
Inclusion
Contact Us
For
Patients
Focus On
Therapies
In the
Community
Resources
Policy on Access to
Unapproved Medicines
Products &
Research
Pipeline
ARCUS® Technology
Products
AMPYRA®
(dalfampridine)
INBRIJA™
(levodopa inhalation powder)
Clinical
Trials
Terms and Conditions
(Product Purchases)
Investors
Corporate
Governance
Stock
Information
Investor Events
Investor News
Financial
Information
Quarterly Updates
Annual Reports
SEC Filings
Analysts
Investor
Resources
Investor Kit
E-mail Alerts
FAQs
IR Contact
News &
Events
In the News
Awards
Press Releases
Social Media
Careers
Working at
Acorda
Our
Employees
Benefits
Job Openings
Application
Privacy Policy
Terms Of Use
Site Map
Contact Us
SEC Filings
All Form Types
Annual Filings
Quarterly Filings
Current Reports
Proxy Filings
Registration Statements
Section 16 Filings
Other Filings
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2001
2000
1999
1998
1997
1996
Date
Filing
Description
Download
11/29/05
S-1/A
Securities Registration Statement
10/05/05
S-1
Securities Registration Statement
Quick Links
View our investor kit
MEET OUR LEADERSHIP TEAM
Board Of Directors
Contact Us
Pipeline
SEC Filings
Email Alerts
Un-subscribe from email alerts
Email Address
*
Mailing Lists
*
News Releases Alert
SEC Alert
Events Alert
Calendar Alert
Text size
Normal
Larger
Largest
Print
ABOUT ACORDA
Company Leadership
Management Team
Board of Directors
Partnering With Acorda
Grant Program
Scientific Award
Compliance
Acorda Compliance
Biotie EFPIA Discolsures
Message From BIO
Diversity and Inclusion
Contact Us
FOR PATIENTS
Focus On Therapies
In The Community
Resources
Policy on Access to
Unapproved or
Uncommericalized
Medicines
PRODUCTS & RESEARCH
Pipeline
ARCUS® Technology
Products
AMPYRA®
(dalfampridine)
INBRIJA™
(levodopa inhalation powder)
Terms and Conditions
(Product Purchases)
Clinical Trials
INVESTORS
Corporate Governance
Stock Information
Investors Events
Investor News
Financial Information
Quarterly Reports
Annual Reports
SEC Filings
Analysts
Investor Resources
Investor Kit
E-mail Alerts
FAQs
IR Contact
NEWS & EVENTS
In The News
Awards
Investor News
Social Media
CAREERS
Working At Acorda
Our Employees
Benefits
Job Openings
Application
Home
|
Privacy Policy
|
Terms Of Use
|
Site Map
|
Contact Us
© Copyright 2017
Powered By Q4 Inc.
5.52.0.6